TP53 and cancer: As expected, the anti-proliferative effect of NTAPP was much more efficient in cancer cells without functional p53 (DLD-1, H1299, HT29, and HCT15) than in cancer cells with wild-type p53 (LoVo, MES-SA, HepG2, and RKO): the relative percentage of viable cells was around 60–80% in p53-negative cancer cells while it was approximately 120–140% in p53-positive cancer cells (Figure 4C).